The Market Reports

Synopsis
Ovarian cancer occurs and arises from several types of cells within the ovary, and it has the lowest survival rate of all gynecological cancers. Among many types, epithelial ovarian cancer (EOC) is the most common ovarian cancer, whereas ovarian low malignant potential tumor (OLMPT), germ cell tumor, and stromal ovarian tumor are some of the less common types. It is the seventh most common cancer in women globally and 18th most common cancer overall. The ovarian cancer immunotherapies market has already got some commercially successful chemotherapy products. However, chemotherapy often involves a combination of two or more drugs, given intravenously every 3-4 weeks, and mostly associated with long-lasting side/adverse effects. Various studies have shown that chemotherapy can damage the blood-producing cells of the bone marrow, resulting in blood-related complications.
The global Gene Therapy for Ovarian Cancer market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Gene Therapy for Ovarian Cancer in various end use industries. The expanding demands from the Ovarian Cancer (Unspecified), Recurrent Ovarian Epithelial Cancer and Platinum-Resistant Ovarian Cancer,, are propelling Gene Therapy for Ovarian Cancer market. Intravenous, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Intratumoral segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Gene Therapy for Ovarian Cancer, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Gene Therapy for Ovarian Cancer market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Gene Therapy for Ovarian Cancer market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Gene Therapy for Ovarian Cancer sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Gene Therapy for Ovarian Cancer covered in this report include Takara Bio, VBL Therapeutics, CELSION and Targovax, etc.
The global Gene Therapy for Ovarian Cancer market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Takara Bio
VBL Therapeutics
CELSION
Targovax
Global Gene Therapy for Ovarian Cancer market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Gene Therapy for Ovarian Cancer market, Segment by Type:
Intravenous
Intratumoral
Intraperitoneal
Global Gene Therapy for Ovarian Cancer market, by Application
Ovarian Cancer (Unspecified)
Recurrent Ovarian Epithelial Cancer
Platinum-Resistant Ovarian Cancer
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Gene Therapy for Ovarian Cancer companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion

Index